Piper Sandler analyst David Amsellem downgraded Eagle Pharmaceuticals to Underweight from Neutral with a price target of $17, down from $26.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EGRX:
- Eagle Pharmaceuticals Reports Second Quarter 2023 Results
- EGRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Eagle Pharmaceuticals to Host Second Quarter 2023 Financial Results on August 8, 2023
- Eagle Pharma raises FY23 adjusted EPS view to $4.40-$4.70 from $4.20-$4.53
- Eagle Pharmaceuticals Raises 2023 Adjusted non-GAAP EPS¹ Guidance